Abstract: The present disclosure provides methods of altering engagement between T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) and phosphatidylserine (PS) in a subject. Also provided are methods of treatment using TIM-3 binding protein wherein the TIM-3 binding domain specifically binds to the C?C? and DE loops of the immunoglobulin variable (IgV) domain of TIM-3.

Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating cancer, in particular, non-small cell lung cancer, comprising an anti-EGFR antibody, preferably necitumumab, in combination with an anti-PD-1 antibody, preferably pembrolizumab.

Abstract: The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors.

Abstract: A method of diagnosing diseases associated with aberrant biological phenotypes including contacting a sample to be tested with at least one isoform of membrane associated progesterone receptor component 1 (mPR) as a diagnostic marker, and determining or estimating the degree of phosphorylation of the membrane associated progresterone receptor component 1 (mPR).

Abstract: Described is a novel marker protein associated with epithelial tumors, e.g., ovarian, mammary, stomach, kidney, thyroid and lung carcinomas, Dropl, a dystrophin-related protein as well as a nucleic acid molecule encoding Dropl. Furthermore, various diagnostic and therapeutic uses based on the finding that the expression of Dropl is downregulated in epithelial tumors are described.